Cargando…

Combining novel agents in chronic lymphocytic leukemia: Greater than the sum of its parts?

Detalles Bibliográficos
Autores principales:	de Weerdt, Iris, Kater, Arnon P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2019
Materias:	Chronic lymphocytic leukemia - Section 5
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8925669/ https://www.ncbi.nlm.nih.gov/pubmed/35309786 http://dx.doi.org/10.1097/HS9.0000000000000197

Ejemplares similares

Genetic predisposition to chronic lymphocytic leukemia
por: Law, Philip J., et al.
Publicado: (2019)

Sialylation regulates migration in chronic lymphocytic leukemia
por: Natoni, Alessandro, et al.
Publicado: (2023)

Subgroup-specific gene expression profiles and mixed epistasis in chronic lymphocytic leukemia
por: Lütge, Almut, et al.
Publicado: (2023)

The immunomodulatory molecule TIGIT is expressed by chronic lymphocytic leukemia cells and contributes to anergy
por: Arruga, Francesca, et al.
Publicado: (2023)

Interleukin-27 potentiates CD8(+) T-cell-mediated antitumor immunity in chronic lymphocytic leukemia
por: Pagano, Giulia, et al.
Publicado: (2023)

Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: pooled analysis of 762 patients
por: Brown, Jennifer R., et al.
Publicado: (2021)

B-cell antigen receptor expression and phosphatidylinositol 3-kinase signaling regulate genesis and maintenance of mouse chronic lymphocytic leukemia
por: Schmid, Vera Kristin, et al.
Publicado: (2022)

A clinical practice comparison of patients with chronic lymphocytic leukemia with and without deletion 17p receiving first-line treatment with ibrutinib
por: Mato, Anthony R., et al.
Publicado: (2022)

First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial
por: Moreno, Carol, et al.
Publicado: (2022)

High rate of durable responses with undetectable minimal residual disease with front-line venetoclax and rituximab in young, fit patients with chronic lymphocytic leukemia and an adverse biological profile: results of the GIMEMA phase II LLC1518 – VERITAS study
por: Mauro, Francesca R., et al.
Publicado: (2023)

A novel next-generation sequencing capture-based strategy to report somatic hypermutation status using genomic regions downstream to immunoglobulin rearrangements
por: McCafferty, Neil, et al.
Publicado: (2022)

The evolving role of Bruton’s tyrosine kinase inhibitors in chronic lymphocytic leukemia
por: Gordon, Max J., et al.
Publicado: (2021)

COVID-19 Pandemic Impact on Chronic Lymphocytic Leukemia (CLL) Patients' Preferences Towards Therapies: The Italian Experience (CHOICE Study)
por: Molica, Stefano, et al.
Publicado: (2021)

Cellular Immune Responses to BNT162b2 mRNA COVID-19 Vaccine in Patients with Chronic Lymphocytic Leukemia
por: Itchaki, Gilad, et al.
Publicado: (2021)

Humoral Response to mRNA Vaccines BNT162b2 and mRNA-1273 COVID-19 in Chronic Lymphocytic Leukemia Patients
por: Bagacean, Cristina, et al.
Publicado: (2021)

Immunotherapy in Chronic Lymphocytic Leukaemia (CLL)
por: Freeman, Ciara L., et al.
Publicado: (2016)

A Clue to Better Select Chronic Lymphocytic Leukemia Patients with Optimal Response to BNT162b2 mRNA COVID-19 Vaccine
por: Molica, Stefano, et al.
Publicado: (2021)

Chronic Lymphocytic Leukemia (CLL) Patients Quality of Life (QoL): A Cross-Sectional Analysis of the Italian Experience in the Choice Study during the First Wave of the COVID-19 Pandemic
por: Tedeschi, Alessandra, et al.
Publicado: (2021)

Chronic myeloid leukemia
por: Hantschel, Oliver
Publicado: (2019)

Cytogenetic and Molecular Predictors of Outcome in Acute Lymphocytic Leukemia: Recent Developments
por: Iacobucci, Ilaria, et al.
Publicado: (2012)

CML-127 Results of a Vaccination Against COVID-19 by a Vector Based Vaccine Sputnik V in Patients With Chronic Myeloid Leukemia
por: Chelysheva, Ekaterina, et al.
Publicado: (2022)

CML-384 Immunological Response to SARS-CoV-2 After Infection and/or Vaccination Among Chronic Myeloid Leukemia Patients – A Prospective Study
por: Galvis, Marisol Miranda, et al.
Publicado: (2022)

COVID-19 Infection in Vaccinated Adult Patients with Hematological Malignancies. Preliminary Results from Epicovideha (Epidemiology of COVID-19 infection in patients with hematological malignancies: A European Haematology Association Survey)
por: Marchesi, Francesco, et al.
Publicado: (2021)

Poor Neutralizing Antibody Responses in Patients with CLL, NHL and HL after Vaccination Against Sars-Cov-2; A Prospective Study in 132 Patients
por: Terpos, Evangelos, et al.
Publicado: (2021)

A Third Anti-Sars-Cov2 mRNA Dose Does Not Overcome the Pejorative Impact of Anti-CD20 Therapy and/or Low Immunoglobulin Level in CLL/Lymphoma Patients
por: Chbat, Maureen, et al.
Publicado: (2021)

Humoral and Cellular Immunogenicity of COVID-19 Vaccinations in Patients with CLL
por: Sun, Clare, et al.
Publicado: (2021)

Evaluation of Antibody Response to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Immunizations in Patients with B-Cell Malignancies
por: Singal, Mukul, et al.
Publicado: (2021)

The role of acalabrutinib in adults with chronic lymphocytic leukemia
por: Fakhri, Bita, et al.
Publicado: (2021)

A rare case of appendicular skeleton localization in a patient with chronic lymphocytic leukemia successfully treated with salvage radiation therapy
por: Tuscano, Carmelo, et al.
Publicado: (2017)

CML-005: Outcome of Haploidentical Hematopoietic Stem Cell Transplantation with a Donor and Recipient with SARS-CoV-2 Infection
por: Ali, Gadallah, et al.
Publicado: (2021)

Role of Epigenetics in Chronic Myeloid Leukemia
por: Machova Polakova, Katerina, et al.
Publicado: (2013)

Is the whole greater than the sum of its parts?
por: Andrews, L, et al.
Publicado: (2012)

Molecular response in newly diagnosed chronic-phase chronic myeloid leukemia: prediction modeling and pathway analysis
por: Radich, Jerald P., et al.
Publicado: (2023)

Obesity and the Risk for a Hematological Malignancy: Leukemia, Lymphoma, or Myeloma
por: Lichtman, Marshall A.
Publicado: (2010)

Patient- and physician-reported pain after tyrosine kinase inhibitor discontinuation among patients with chronic myeloid leukemia
por: Flynn, Kathryn E., et al.
Publicado: (2022)

RHOA-regulated IGFBP2 promotes invasion and drives progression of BCR-ABL1 chronic myeloid leukemia
por: Zhang, Hualei, et al.
Publicado: (2022)

Response to imatinib mesylate in childhood chronic myeloid leukemia in chronic phase
por: Linga, Vijay Gandhi, et al.
Publicado: (2014)

Differential inhibition of T-cell receptor and STAT5 signaling pathways determines the immunomodulatory effects of dasatinib in chronic phase chronic myeloid leukemia
por: Harrington, Patrick, et al.
Publicado: (2023)

Impact of additional genetic abnormalities at diagnosis of chronic myeloid leukemia for first-line imatinib-treated patients receiving proactive treatment intervention
por: Shanmuganathan, Naranie, et al.
Publicado: (2023)

IL-18 and VEGF-A trigger type 2 innate lymphoid cell accumulation and pro-tumoral function in chronic myeloid leukemia
por: Fiordi, Benedetta, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_6b3rjus92prub66n323pf4gain